001     137434
005     20240321220240.0
024 7 _ |a 10.1111/jnc.12668
|2 doi
024 7 _ |a pmid:24479685
|2 pmid
024 7 _ |a 0022-3042
|2 ISSN
024 7 _ |a 1471-4159
|2 ISSN
024 7 _ |a altmetric:2213602
|2 altmetric
037 _ _ |a DZNE-2020-03756
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Kuß, Martin
|0 P:(DE-2719)2801327
|b 0
|e First author
245 _ _ |a Interferon-γ induces leucine-rich repeat kinase LRRK2 via extracellular signal-regulated kinase ERK5 in macrophages.
260 _ _ |a Oxford
|c 2014
|b Wiley-Blackwell
264 _ 1 |3 online
|2 Crossref
|b Wiley
|c 2014-02-24
264 _ 1 |3 print
|2 Crossref
|b Wiley
|c 2014-06-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1591615548_4057
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The gene encoding leucine-rich repeat kinase 2 (LRRK2) comprises a major risk factor for Parkinson's disease. Recently, it has emerged that LRRK2 plays important roles in the immune system. LRRK2 is induced by interferon-γ (IFN-γ) in monocytes, but the signaling pathway is not known. Here, we show that IFN-γ-mediated induction of LRRK2 was suppressed by pharmacological inhibition and RNA interference of the extracellular signal-regulated kinase 5 (ERK5). This was confirmed by LRRK2 immunostaining, which also revealed that the morphological responses to IFN-γ were suppressed by ERK5 inhibitor treatment. Both human acute monocytic leukemia THP-1 cells and human peripheral blood monocytes stimulated the ERK5-LRRK2 pathway after differentiation into macrophages. Thus, LRRK2 is induced via a novel, ERK5-dependent IFN-γ signal transduction pathway, pointing to new functions of ERK5 and LRRK2 in human macrophages. Leucine-rich repeat kinase 2 (LRRK2) is a major risk factor for the development of Parkinson's disease (PD). However, the role of LRRK2 in the affected neurons remains enigmatic. Recently, LRRK2 has been reported to be strongly expressed in the immune system. Here, we demonstrate that LRRK2 is induced by Interferon gamma via extracellular signal-regulated kinase 5 (ERK5) in macrophages, thus providing new insights in LRRK2 and ERK5 biology.
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 0
536 _ _ |a 345 - Population Studies and Genetics (POF3-345)
|0 G:(DE-HGF)POF3-345
|c POF3-345
|f POF III
|x 1
542 _ _ |i 2015-09-01
|2 Crossref
|u http://doi.wiley.com/10.1002/tdm_license_1.1
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Cytokines
|2 NLM Chemicals
650 _ 7 |a Enzyme Inhibitors
|2 NLM Chemicals
650 _ 7 |a Interferon-gamma
|0 82115-62-6
|2 NLM Chemicals
650 _ 7 |a LRRK2 protein, human
|0 EC 2.7.11.1
|2 NLM Chemicals
650 _ 7 |a Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
|0 EC 2.7.11.1
|2 NLM Chemicals
650 _ 7 |a Protein-Serine-Threonine Kinases
|0 EC 2.7.11.1
|2 NLM Chemicals
650 _ 7 |a Mitogen-Activated Protein Kinase 7
|0 EC 2.7.11.24
|2 NLM Chemicals
650 _ 2 |a Protein Serine-Threonine Kinases: biosynthesis
|2 MeSH
650 _ 2 |a Blotting, Western
|2 MeSH
650 _ 2 |a Cells, Cultured
|2 MeSH
650 _ 2 |a Cytokines: metabolism
|2 MeSH
650 _ 2 |a Enzyme Induction: drug effects
|2 MeSH
650 _ 2 |a Enzyme Inhibitors: pharmacology
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Immunohistochemistry
|2 MeSH
650 _ 2 |a Interferon-gamma: antagonists & inhibitors
|2 MeSH
650 _ 2 |a Interferon-gamma: pharmacology
|2 MeSH
650 _ 2 |a Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
|2 MeSH
650 _ 2 |a Macrophages: drug effects
|2 MeSH
650 _ 2 |a Macrophages: enzymology
|2 MeSH
650 _ 2 |a Mitogen-Activated Protein Kinase 7: antagonists & inhibitors
|2 MeSH
650 _ 2 |a Mitogen-Activated Protein Kinase 7: physiology
|2 MeSH
650 _ 2 |a Protein-Serine-Threonine Kinases: biosynthesis
|2 MeSH
650 _ 2 |a Real-Time Polymerase Chain Reaction
|2 MeSH
650 _ 2 |a Signal Transduction: drug effects
|2 MeSH
700 1 _ |a Adamopoulou, Eleni
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Kahle, Philipp J
|0 P:(DE-2719)2810803
|b 2
|e Last author
773 1 8 |a 10.1111/jnc.12668
|b : Wiley, 2014-02-24
|n 6
|p 980-987
|3 journal-article
|2 Crossref
|t Journal of Neurochemistry
|v 129
|y 2014
|x 0022-3042
773 _ _ |a 10.1111/jnc.12668
|g Vol. 129, no. 6, p. 980 - 987
|0 PERI:(DE-600)2020528-4
|n 6
|q 129:6<980 - 987
|p 980-987
|t Journal of neurochemistry
|v 129
|y 2014
|x 0022-3042
909 C O |p VDB
|o oai:pub.dzne.de:137434
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2801327
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2810803
913 1 _ |a DE-HGF
|b Forschungsbereich Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|2 G:(DE-HGF)POF3-300
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Forschungsbereich Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-345
|2 G:(DE-HGF)POF3-300
|v Population Studies and Genetics
|x 1
914 1 _ |y 2014
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEUROCHEM : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 _ _ |l no
920 1 _ |0 I:(DE-2719)1240015
|k AG N.N. 3
|l AG N.N.
|x 0
920 1 _ |0 I:(DE-2719)1210000-4
|k AG Kahle 2
|l Functional Neurogenetics
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1240015
980 _ _ |a I:(DE-2719)1210000-4
980 _ _ |a UNRESTRICTED
999 C 5 |a 10.1038/ng.175
|9 -- missing cx lookup --
|2 Crossref
|o 10.1038/ng.175
999 C 5 |a 10.1038/nrn2935
|9 -- missing cx lookup --
|2 Crossref
|o 10.1038/nrn2935
999 C 5 |a 10.1016/j.bbrc.2008.11.048
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.bbrc.2008.11.048
999 C 5 |a 10.1038/nchembio.538
|9 -- missing cx lookup --
|2 Crossref
|o 10.1038/nchembio.538
999 C 5 |a 10.1242/jcs.070516
|9 -- missing cx lookup --
|2 Crossref
|o 10.1242/jcs.070516
999 C 5 |a 10.1042/BJ20100784
|9 -- missing cx lookup --
|2 Crossref
|o 10.1042/BJ20100784
999 C 5 |a 10.1128/MCB.01246-12
|9 -- missing cx lookup --
|2 Crossref
|o 10.1128/MCB.01246-12
999 C 5 |a 10.1002/ana.20808
|9 -- missing cx lookup --
|2 Crossref
|o 10.1002/ana.20808
999 C 5 |a 10.4049/jimmunol.1000548
|9 -- missing cx lookup --
|2 Crossref
|o 10.4049/jimmunol.1000548
999 C 5 |a 10.1093/emboj/18.20.5601
|9 -- missing cx lookup --
|2 Crossref
|o 10.1093/emboj/18.20.5601
999 C 5 |a 10.1186/1742-2094-9-94
|9 -- missing cx lookup --
|2 Crossref
|o 10.1186/1742-2094-9-94
999 C 5 |a 10.1007/s00702-011-0653-2
|9 -- missing cx lookup --
|2 Crossref
|o 10.1007/s00702-011-0653-2
999 C 5 |a 10.1007/s00109-004-0602-8
|9 -- missing cx lookup --
|2 Crossref
|o 10.1007/s00109-004-0602-8
999 C 5 |a 10.1158/0008-5472.CAN-04-4555
|9 -- missing cx lookup --
|2 Crossref
|o 10.1158/0008-5472.CAN-04-4555
999 C 5 |a 10.1038/ni.2113
|9 -- missing cx lookup --
|2 Crossref
|o 10.1038/ni.2113
999 C 5 |a 10.1111/jnc.12483
|9 -- missing cx lookup --
|2 Crossref
|o 10.1111/jnc.12483
999 C 5 |a 10.1523/JNEUROSCI.5601-11.2012
|9 -- missing cx lookup --
|2 Crossref
|o 10.1523/JNEUROSCI.5601-11.2012
999 C 5 |a 10.1074/jbc.M704079200
|9 -- missing cx lookup --
|2 Crossref
|o 10.1074/jbc.M704079200
999 C 5 |a 10.1042/BJ20091035
|9 -- missing cx lookup --
|2 Crossref
|o 10.1042/BJ20091035
999 C 5 |a 10.1016/j.cellsig.2012.07.007
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.cellsig.2012.07.007
999 C 5 |a 10.1016/j.neuron.2004.10.023
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.neuron.2004.10.023
999 C 5 |a 10.1021/cb2002413
|9 -- missing cx lookup --
|2 Crossref
|o 10.1021/cb2002413
999 C 5 |a 10.1038/ng.485
|9 -- missing cx lookup --
|2 Crossref
|o 10.1038/ng.485
999 C 5 |a 10.1038/ng.487
|9 -- missing cx lookup --
|2 Crossref
|o 10.1038/ng.487
999 C 5 |a 10.1042/BST20120151
|9 -- missing cx lookup --
|2 Crossref
|o 10.1042/BST20120151
999 C 5 |a 10.1016/j.bbrc.2008.09.087
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.bbrc.2008.09.087
999 C 5 |a 10.4049/jimmunol.180.7.4523
|9 -- missing cx lookup --
|2 Crossref
|o 10.4049/jimmunol.180.7.4523
999 C 5 |a 10.1038/icb.2012.9
|9 -- missing cx lookup --
|2 Crossref
|o 10.1038/icb.2012.9
999 C 5 |a 10.1016/j.ccr.2010.08.008
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.ccr.2010.08.008
999 C 5 |a 10.3389/fphys.2012.00171
|9 -- missing cx lookup --
|2 Crossref
|o 10.3389/fphys.2012.00171
999 C 5 |a 10.1016/S1353-8020(11)70056-6
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/S1353-8020(11)70056-6
999 C 5 |a 10.1056/NEJMoa0903753
|9 -- missing cx lookup --
|2 Crossref
|o 10.1056/NEJMoa0903753
999 C 5 |a 10.1016/j.bmcl.2012.01.084
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.bmcl.2012.01.084
999 C 5 |a 10.1016/j.neuron.2004.11.005
|9 -- missing cx lookup --
|2 Crossref
|o 10.1016/j.neuron.2004.11.005


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21